Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Annaswamy Raji"'
Autor:
Lisa Tarasenko, Annpey Pong, Roberto A. Calle, Annaswamy Raji, Silvina Gallo, Steven G. Terra
Publikováno v:
Diabetes Therapy
Introduction This post hoc exploratory analysis examined the effects of ertugliflozin on liver enzymes in patients with type 2 diabetes mellitus (T2DM). Methods Data were pooled from seven randomized, double-blind VERTIS phase 3 trials that evaluated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab1e462bab0efbdf7c2b6e0b1670d0da
http://europepmc.org/articles/PMC7376773
http://europepmc.org/articles/PMC7376773
Autor:
Annaswamy Raji, Hakima Hannachi, Annpey Pong, Steven G. Terra, Jie Liu, Steven B. Heymsfield, Silvina Gallo
Publikováno v:
Obesity (Silver Spring, Md.)
OBJECTIVE This study aimed to evaluate ertugliflozin in patients with overweight and obesity with type 2 diabetes mellitus. METHODS Data from three placebo-controlled, randomized, Phase 3 studies were pooled. Patients with baseline BMI ≥ 25 (1,377/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fcfa12aaf948f93d09c4eaa5313315c
http://europepmc.org/articles/PMC7217180
http://europepmc.org/articles/PMC7217180
Autor:
James P. Mancuso, Weichung Shih, Ira Gantz, Jie Liu, Annaswamy Raji, Robert Frederich, Darren K. McGuire, Richard E. Pratley, Samuel Dagogo-Jack, Francesco Cosentino, David Z.I. Cherney
Publikováno v:
BMJ Open Diabetes Research & Care
IntroductionHere we report the glycemic efficacy and safety of ertugliflozin in patients in the VERTIS CV cardiovascular outcome trial with chronic kidney disease (CKD) stage 3.Research design and methodsPrespecified and post-hoc analyses were perfor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c968fbf20f76ec9ba6c6d5cb1efbb148
http://europepmc.org/articles/PMC8499340
http://europepmc.org/articles/PMC8499340
Autor:
Annaswamy Raji, Richard E. Pratley, Bernard Charbonnel, Samuel Dagogo-Jack, Francesco Cosentino, Weichung Shih, Jie Liu, Ira Gantz, James P. Mancuso, Robert Frederich, Darren K. McGuire, David Z.I. Cherney
Publikováno v:
Diabetes. 70
VERTIS CV was a cardiovascular (CV) outcome trial that evaluated the CV safety of ERTU in patients with T2D and atherosclerotic CV disease (ASCVD). This analysis assessed the glycemic efficacy and safety of ERTU in VERTIS CV patients with CKD 3. Amon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c6a18a47c261c89f87c357f5b27bf0b
https://doi.org/10.2337/db21-786-p
https://doi.org/10.2337/db21-786-p
Autor:
Michael F. Egan, Saheeda Jackson, Cyrille Sur, Robert C. Sergott, James Kost, Christine Furtek, Annaswamy Raji, Amy Locco, Britta A. Mattson, Arpankumar Patel
Publikováno v:
Journal of Alzheimer's disease : JAD. 79(1)
Background: We performed exploratory analyses of retinal thickness data from a clinical trial of the AβPP cleaving enzyme (BACE) inhibitor verubecestat in patients with Alzheimer’s disease (AD). Objective: To evaluate: 1) possible retinal thicknes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddc9bf12a74e0f0c4b00e601d976d4aa
https://pubmed.ncbi.nlm.nih.gov/33252075
https://pubmed.ncbi.nlm.nih.gov/33252075
Publikováno v:
Diabetes, obesitymetabolismREFERENCES. 22(12)
AIM To identify potential predictors and mediators of changes in β-cell function in response to ertugliflozin treatment in people with type 2 diabetes mellitus (T2DM). PARTICIPANTS AND METHODS Data from patients with T2DM randomized to ertugliflozin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7401d1277b8450d8eb7b6effddf752c3
https://pubmed.ncbi.nlm.nih.gov/32700393
https://pubmed.ncbi.nlm.nih.gov/32700393
Autor:
Jerry D. Morgan, Zachary Zimmer, Annaswamy Raji, Russell S. Scott, Samuel S. Engel, Raymond L. H. Lam, Edward A. O'Neill, Keith D. Kaufman
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To compare the efficacy and safety of the dipeptidyl peptidase‐4 inhibitor sitagliptin with the sodium‐glucose transporter‐2 inhibitor dapagliflozin in patients with type 2 diabetes and mild renal insufficiency. Materials and Methods Patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5813d5152ad9f3046123abcb26d8467
http://europepmc.org/articles/PMC6283039
http://europepmc.org/articles/PMC6283039
Publikováno v:
Diabetes. 68
Improving glycemic control generally improves β-cell function in T2DM but the predictors for this effect are unclear. SGLT2 inhibitors improve glycemia and have no known direct effects on β-cell function. Therefore, we aimed to identify predictors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e7bcacc25984db4cd4d38e7dfe8ed986
https://doi.org/10.2337/db19-1232-p
https://doi.org/10.2337/db19-1232-p
Autor:
Zachary Zimmer, Annaswamy Raji, Edward A. O'Neill, Keith D. Kaufman, Jerry D. Morgan, Raymond L. H. Lam, Russell S. Scott, Samuel S. Engel
Publikováno v:
Diabetes. 67
While choice of AHAs may be modified in patients with T2D and moderate or severe renal insufficiency, this is generally not the case in patients with mild renal insufficiency. Clinical trial data focused on this population, which represents ∼40% of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::006c665c2089e442df027bf12cae09bd
https://doi.org/10.2337/db18-1142-p
https://doi.org/10.2337/db18-1142-p
Autor:
Gregory T. Golm, Roy Eldor, Annaswamy Raji, Yanping Qiu, Susan Huyck, James P. Mancuso, Sheila Sunga, Steven G. Terra, Brett Lauring, Jeremy Johnson, Samuel S. Engel, Richard E. Pratley
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To evaluate the efficacy and safety of ertugliflozin and sitagliptin co‐administration vs the individual agents in patients with type 2 diabetes who are inadequately controlled with metformin. Methods In this study (http://Clinicaltrials.gov NC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4cbc2c5b81423bd70631fa9bec1f5c4
https://pubmed.ncbi.nlm.nih.gov/29266675
https://pubmed.ncbi.nlm.nih.gov/29266675